Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rabih Fahed (NPI 1043488844)

Field	Value
Entity Type	Individual
Organization	Rabih Fahed
Address	110 N 29th St
City	Norfolk
State	NE
ZIP	68701
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	February 14, 2008

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider is a hematology & oncology physician with a Medicare lifetime revenue footprint of $2M and no Medicaid billing on file, making their practice effectively single-payer (Medicare) in the available claims data. The NPI shows long tenure, enumerated ~2008-02-14 (~18 years ago), consistent with an established practice likely serving a stable Medicare patient panel.

Revenue concentration is high: the top 3 Medicare codes by revenue account for 70.6% of this provider's total Medicare revenue, indicating that a small set of drug administration codes—most notably J9271—drive the majority of billing. This concentration suggests a practice built around high-cost oncology infusions or biologic therapies rather than a broad mix of outpatient services.

J9271 (pembrolizumab) is the single largest revenue driver at $980.4K (50.2% of Medicare revenue) and shows typical national volume for the code (84th percentile, rank #283/1841). The dominance of J9271 indicates the practice delivers substantial checkpoint inhibitor therapy, positioning infusion/oncologic drug administration as the clinic’s core service line.

J0897 (denosumab) contributes $267.8K (13.7% of Medicare revenue) and ranks in the 95th percentile nationally (#549/10057), a notably above-typical volume for that code. Combined with strong billing for supportive oncology drugs and biosimilars like Q5107 (mvasi) at $130.4K (6.7%), the mix points to both cancer-directed therapy and associated bone-health/supportive care as routine components of the service mix.

Several chemotherapy administration and infusion-related E/M and procedure codes show unusually high national standing: 99214 ranks in the 98th percentile and is described as an extreme outlier, 96416 ranks in the 98th percentile (#3/117), and codes like 96367, 96401, 96417, 96415, 96372, and 96411 are all flagged as notably above typical national volume (range of high percentiles). These patterns underscore a high-volume infusion practice with frequent chemotherapy and complex infusion management encounters compared with peers.

Although many drug codes have high claim counts, not all are high-dollar per-claim; examples include J1439 ($38.3K revenue at $1 avg paid/claim) and J0881 ($36.7K revenue at $2 avg paid/claim), indicating substantial utilization of lower-paid per-unit injectable products alongside expensive biologics. This blend is consistent with hematology/oncology workflows that combine high-cost immunotherapies with lower-cost supportive agents billed per milligram or unit.

Competitive standing is mixed by code: for some high-revenue biologics the provider is a typical to modest national participant (J9271 at 84th percentile is unremarkable volume), whereas for numerous infusion and administration codes the provider ranks among the very highest users nationally (multiple codes in the 97th–100th percentiles and specific ranks like #3 or #9). This suggests the clinic is a major infusion provider locally or regionally even if it is not universally dominant across every high-cost drug class.

The absence of any Medicaid billing on file means there is no observable in-state Medicaid activity to compare; payer mix is therefore highly skewed toward Medicare in the available data. For payer strategy or network planning, this provider should be treated as essentially Medicare-focused based on the claims dataset, and any Medicaid contracting or access assumptions should be validated through additional sources.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

49 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,800	$40	$980.4K
J0897	Injection, denosumab, 1 mg	14,880	$20	$267.8K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	5,670	$20	$130.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,140	$80	$94.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	770	$90	$71.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	550	$90	$48.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	370	$130	$48.2K
J1439	Injection, ferric carboxymaltose, 1 mg	38,250	$1	$38.3K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	110	$350	$37.9K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	440	$80	$37.3K

Showing 1–10 of 49

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 49 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Rabih Fahed — 13 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

49 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	30	14,400	$40	$671.6K
Q5107	2	10	5,670	$20	$138.2K
J0897	5	200	2,040	$20	$62.7K
J0881	6	10	17,260	$1	$54.5K
J1454	3	10	110	$350	$41.5K
J2506	3	20	460	$90	$40.5K
Q5108	3	10	410	$90	$35.7K
J1439	8	30	25,880	$1	$26.4K
96413	2	80	60	$90	$18.2K
99214	54	3,210	110	$70	$14.9K

Showing 1–10 of 49

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rabih Fahed, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Chad Laurich	SD	Vascular Surgery Physician	$3.2M	$0
Samer Renno	NE	Hematology & Oncology Physician	$3.2M	$0
Inaganti Shah	NE	Hematology & Oncology Physician	$2M	$0
Providence Medical Center	NE	Critical Access Hospital	$0	$592.6K
Hematology & Oncology Consultants, PC	NE	Hematology & Oncology Physician	$0	$578.6K
Abraham Mathews	NE	Hematology & Oncology Physician	$369.1K	$0
Jose Gary Nadala	NE	Child & Adolescent Psychiatry Physician	$30.1K	$279.5K
Mei He	SD	Neurology Physician	$298.6K	$0
Hadi Zahra	NE	Radiation Oncology Physician	$200.2K	$0
Ryan Martin	NE	Pulmonary Disease Physician	$192.3K	$0

Nearby Providers

Other providers in the same ZIP code as Rabih Fahed, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Midtown Health Center, Inc.	NE	Federally Qualified Health Center (FQHC)	$0	$10.1M
Faith Regional Health Services	NE	General Acute Care Hospital	$0	$7.3M
Faith Regional Physician Services, LLC	NE	Family Medicine Physician	$0	$5.5M
Behavioral Health Specialists Sunrise Place	NE	Substance Abuse Rehabilitation Facility	$0	$4.6M
Children & Adoleseant Clinic PC	NE	Pediatrics Physician	$0	$4.3M
The Well Ne	NE	Substance Abuse Rehabilitation Facility	$0	$3.1M
Nmg LLC	NE	Family Medicine Physician	$0	$2.9M
Cor Therapeutic Services, LLC	NE	Mental Health Counselor	$0	$2.2M
Oasis Counseling International	NE	Mental Health Counselor	$0	$2M
Liberty Centre Services, Inc.	NE	Case Manager/Care Coordinator	$0	$1.6M

Rabih Fahed — Billing Profile & Reimbursement Data

Sign up for Rabih Fahed — Billing Profile & Reimbursement Data policy alerts

Rabih Fahed — Billing Profile & Reimbursement Data

Sign up for Rabih Fahed — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References